Artificial intelligence is rapidly reshaping biotech industries, from drug discovery to bioprocess manufacturing. A bibliometric study uncovered exponential growth in AI-related biotech publications post-2015, linked to computational advances and interdisciplinary collaboration. Concurrently, MIT researchers released the first publicly available AI model predicting long-term stability of CHO cells used in biotherapeutic production, guiding manufacturing consistency. These developments are enabling data-driven quality prediction, automation, and accelerated therapeutic innovation, reflecting a paradigm shift towards integrating AI comprehensively in biotech workflows.